User:Mr. Ibrahem/Atezolizumab
 Antigen-binding fragment of atezolizumab (pale blue) in complex with PD-L1 (pink).PDB: 5X8L. | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | PD-L1 |
| Clinical data | |
| Trade names | Tecentriq |
| Other names | MPDL3280A, RG7446 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a616035 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Intravenous infusion |
| Drug class | Antineoplastic agent |
| Legal status | |
| Legal status | |
| Chemical and physical data | |
| Formula | C6446H9902N1706O1998S42 |
| Molar mass | 144612.59 g·mol−1 |
Atezolizumab, sold under the brand name Tecentriq, is a medication used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), hepatocellular carcinoma (HCC), triple-negative breast cancer, and melanoma.[2][3] Use is often only when specific mutations are present.[2][3] It is given by gradual injection into a vein.[4]
Common side effects include tiredness, reduced appetite, nausea, cough, difficulty breathing, diarrhea, rash, fever, muscle pain, weakness, itching, and urinary tract infection.[3] Other side effects may include immune-mediated disorders including pneumonitis, colitis, and hepatitis.[2] Use in pregnancy may harm the baby.[2] It is a monoclonal antibody that attaches to and blocks programmed cell death-ligand 1 (PD-L1).[3] This allows the immune system to attack cancer cells.[3]
Atezolizumab was approved for medical use in the United States in 2016 and Europe in 2017.[2][3] In the United Kingdom 1.2 grams costs the NHS about £3,800 as of 2021.[4] This amount in the United States costs about 10,300 USD.[5]
References[edit]
- ^ "Tecentriq 1,200 mg concentrate for solution for infusion - Summary of Product Characteristics (SmPC)". (emc). Archived from the original on 4 May 2021. Retrieved 4 March 2020.
- ^ a b c d e f g "Tecentriq- atezolizumab injection, solution". DailyMed. 3 June 2020. Archived from the original on 4 May 2021. Retrieved 31 July 2020.
- ^ a b c d e f g h i "Tecentriq EPAR". European Medicines Agency. Archived from the original on 24 May 2021. Retrieved 31 July 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ a b BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 908. ISBN 978-0857114105.
- ^ "Tecentriq Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 20 April 2021. Retrieved 16 January 2022.